Mymetics Corp (MYMX)

[FALCON1]

Dr. Thomas Monath #2 as well. I remember there was a press release in 2012 regarding his appointment as Chief Medical Officer together with Dr. George Kemble (3-V Biosciences CEO/CSO)as Director when Dr. Grant Pickering (now Sutravax CEO http://sutrovax.com/about-us/management-team/ )and Dr. Christopher Henney (Co-Founder & CEO/Board Chairman of Dendreon Corp.) came on board http://www.xconomy.com/san-francisco/2012/04/11/mymetics-ropes-in-dendreon-kpcb-vets-to-restart-vaccine-developer/. I can't find it in the company and SEC archives.


Here's what I found:


Executive Profile
Thomas P. Monath M.D.
Chief Scientific Officer and Chief Operations Officer of Infectious Disease Division, NewLink Genetics Corporation
Age Total Calculated Compensation This person is connected to 4 Board Members in 4 different organizations across 16 different industries.

See Board Relationships
75 --
Background
Dr. Thomas P. Monath, also known as Tom, M.D., has been the Chief Scientific and Chief Operations Officer at BioProtection Systems Corporation since November 2014. Dr. Monath serves as Chief Operations Officer of Infectious Disease Division and Chief Scientific Officer of NewLink Genetics Corporation. He joined NewLink Genetics in 2014. He serves as an Advisor of Metabiota, Inc. He serves as the Chief Medical Officer of HX Diagnostics, Inc. He served as Consulting Chief Medical Officer of Mymetics Corporation since August 2012. He served as a Director, Division of Vector-Borne Viral Diseases at U.S. Centers For Disease Control And Prevention (cdc). He served as a Venture Partner and Partner at KPCB Pandemic and Bio Defense Fund at Kleiner Perkins Caufield & Byers. Dr. Monath has devoted his nearly 30-year career to the fight against infectious disease through his work in the military, corporate, academic and investment sectors. He was a Venture Partner and Partner at Kleiner, Perkins, Caufield & Byers. He served as the Chief Technology Officer of PaxVax Corporation since February 2012. He served as the Chief of the Virology Division at U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID). Dr. Monath was an Investment Partner at USAMRIID. He served as the Chief Scientific Officer and Executive Director at Sanofi Pasteur Holding Limited (Acambis Plc) from 1992 to 2006, where Dr. Monath directed research and development on dengue, West Nile, Japanese encephalitis, yellow fever, Clostridium difficile and smallpox vaccines for defense against bioterrorism. He served as Acting Chief Medical Officer of Juvaris BioTherapeutics Inc. He served as Vice President of Research and Medical Affairs at Sanofi Pasteur Biologics Co. since December 1993. Dr. Monath served as a Vice President of Research and Development at Oravax Inc from April 1992 to December 1993. He served as Consultant at Oravax Inc. from October 1991 to March 1992. He served as Director of Division of Vector-Borne Viral Diseases at U.S. Centers for Disease Control, Fort Collins CO, from 1973 and 1988. He served as the Chief of Virology Division in United States Medical Research Institute of Infectious Diseases from 1989 to 1992. Dr. Monath joined Kleiner, Perkins, Caufield & Byers in June 26, 2006 and is a part of the life sciences team and specializes in pandemic and Biodefence investments. He retired from the United States army in 1992 after 24 years in the uniformed services. He served as Executive Director at Sanofi Pasteur Holding Limited (Acambis Plc )from 1992 to 2006. He has been a Director of Rapid Micro Biosystems, Inc. since July 2009. He served as a Director of Juvaris BioTherapeutics, Inc. since January 5, 2007 and VaxInnate Corporation since June 2015. He serves as a Member of Advisory Board of SmartVet USA Inc. He is a Member of Scientific Advisory Board at SutroVax, Inc. He serves as a Director of Acambis Plc. He served as a Director of Xcellerex, Inc. He served as a Director of Novavax Inc. from September 2006 to November 2, 2009. He served as a Member of Medical Advisory Board at Symphogen A/S. Dr. Monath is a world-renowned virologist and vaccinologist with over 25 years of experience as a senior biotechnology industry executive, more than 20 years of experience providing service to the Centers for Disease Control and the United States Army with expertise in viral infections and almost 400 publications in the field. Dr. Monath has successfully developed and provided clinical trial oversight of multiple vaccines and has extensive experience and success working with the US Food and Drug Administration. He is on the editorial board of five scientific journals. Dr. Monath received the Nathanial A. Young Award in 1984, the Richard M. Taylor Award in 1996 and the Walter Reed Medal in 2002 from the American Society of Tropical Medicine & Hygiene and was President of that Society from 2004 to 2005. He is an Adjunct Professor at the Harvard School of Public Health. He has published over 40 patents on various products, 380 papers and edited six books on the epidemiology, immunology and pathogenesis of viruses and on vaccine development. In 1992, he retired as a U.S. Army colonel following 24 years in the uniformed services. He trained in Internal Medicine at the Peter Bent Brigham Hospital, Boston. Dr. Monath received an M.D. from Harvard Medical School and a B.A. from Harvard College.